Tradewinds Capital Management LLC Boosts Stake in Novo Nordisk A/S (NYSE:NVO)

Tradewinds Capital Management LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 1st quarter, Holdings Channel reports. The firm owned 5,055 shares of the company’s stock after buying an additional 100 shares during the period. Tradewinds Capital Management LLC’s holdings in Novo Nordisk A/S were worth $649,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. Pacific Center for Financial Services increased its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. First PREMIER Bank acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $25,000. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $26,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $26,000. Finally, West Paces Advisors Inc. increased its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after acquiring an additional 150 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 3.6 %

NYSE NVO traded down $5.20 during trading hours on Wednesday, hitting $137.78. The company had a trading volume of 5,384,472 shares, compared to its average volume of 4,464,806. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $148.15. The company has a market capitalization of $618.29 billion, a price-to-earnings ratio of 48.68, a P/E/G ratio of 1.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The firm’s 50 day moving average is $135.69 and its 200 day moving average is $124.37.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. Argus upped their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.